A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Principal Investigator
-
Sponsor
Acepodia
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of
ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies
Enrollment Form
This study is currently enrolling.